Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Multimorbidity and Polypharmacy in People With HIV vs. the General Population in the Basque Country

10. června 2026 aktualizováno: Biogipuzkoa Health Research Institute

A Comparative Study on the Prevalence of Multimorbidity, Polypharmacy and Potentially Inappropriate Prescriptions Among the General Population and People Living With HIV in the Basque Country

People living with HIV now have a life expectancy similar to that of the general population, thanks to major advances in antiretroviral treatment. As they live longer, many of them experience multiple health conditions at the same time and take several medications, often more than people without HIV. In our region, 6,273 people are currently receiving antiretroviral therapy. However, the new care pathway designed for patients with multiple chronic conditions in the Basque Country's public health system does not include people with HIV. At the same time, we lack local data on how common multimorbidity, polypharmacy, and potentially inappropriate prescribing are among this group. These gaps motivated our study. Our goal is to estimate how frequent these issues are among all people with HIV who receive care in the infectious disease departments of the hospitals in Araba, Basurto, Galdakao, Cruces, and Donostia, and to compare them with a similar group of people without HIV. To do this, we designed a cross-sectional study including the 6,273 people with HIV and a control group from the general population, selected to match them by age, sex, and health centre. By analysing data from electronic health records, we aim to determine whether people with HIV have higher rates of multimorbidity, polypharmacy, and inappropriate prescribing than the general population. The findings from both groups will help us update the care pathway and improve coordinated care for HIV-positive patients with multiple health conditions.

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Intervence / Léčba

Detailní popis

Advances in antiretroviral treatment for people living with Human Immunodeficiency Virus (HIV) have brought their life expectancy into line with that of the general population. These individuals now have a higher prevalence of multiple co-morbidities and polypharmacy than the general population.

According to the latest report on the AIDS plan, there are 6,273 patients in our region currently receiving antiretroviral treatment. However, the recent corporate care pathway for people with multiple co-morbidities in the Basque Country's public health system does not include patients with HIV. This fact, together with the lack of data on the prevalence of multiple co-morbidities, polypharmacy and potentially inappropriate prescribing among these individuals in our region, motivated the conduct of this study. Its aim is to estimate this prevalence among all people with HIV receiving care in the infectious diseases departments of the hospitals in Araba, Basurto, Galdakao, Cruces and Donostia, and to compare it with a control group without HIV. To this end, we designed a cross-sectional comparative study involving 6,273 people with HIV and a control group drawn from the general population through stratified sampling according to the distribution by age, sex and health centre of the HIV population. The results, obtained by extracting data from electronic health records, will enable us to confirm whether the HIV-positive population has a higher prevalence of multimorbidity, polypharmacy and inappropriate prescribing than the general population. The results obtained from both populations will provide us with the necessary knowledge to update the corporate care pathway and to plan coordinated care for HIV-positive patients with multimorbidity.

Typ studie

Pozorovací

Zápis (Odhadovaný)

12546

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dospělý
  • Starší dospělý

Přijímá zdravé dobrovolníky

Ano

Metoda odběru vzorků

Ukázka pravděpodobnosti

Studijní populace

People with HIV aged 18 or over who are being monitored by the infectious diseases departments of the Araba, Cruces, Basurto and Donostia University Hospitals and the Galdakao-Usansolo Hospital, all part of Osakidetza. Five HIV-negative controls will be selected for each person with HIV. Stratified random sampling will be carried out by age, sex and referral hospital, according to the composition of the HIV population.

Popis

Inclusion Criteria:

  • People with HIV aged 18 or over
  • Being monitored by the infectious diseases departments of the Araba, Cruces, Basurto and Donostia University Hospitals and the Galdakao-Usansolo Hospital, all part of Osakidetza.

Exclusion Criteria:

- Being under 18 years of age

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

Kohorty a intervence

Skupina / kohorta
Intervence / Léčba
People with HIV
People with HIV aged 18 years or over receiving care in the infectious diseases departments of the hospitals in Araba, Basurto, Galdakao, Cruces and Donostia.
Jiný: Žádný zásah
Žádný zásah
General population
General population through stratified sampling according to the distribution by age, sex and health centre of the HIV population
Jiný: Žádný zásah
Žádný zásah

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Prevalence of multimorbidity in people with HIV in the Basque Country
Časové okno: Enrollment
Proportion of people with HIV aged ≥18 years who have ≥2 chronic diseases recorded in their electronic health records. Automated extraction of active diagnoses coded in the electronic health records.
Enrollment
Prevalence of multimorbidity in the general population in the Basque Country
Časové okno: Enrollment
Proportion of people aged ≥18 years who have ≥2 chronic diseases recorded in their electronic health record. Automated extraction of active diagnoses coded in the electronic health records.
Enrollment
Prevalence of polypharmacy in people with HIV in the Basque Country
Časové okno: Enrollment
Proportion of people with HIV aged ≥18 years who have ≥5 prescribed medications and ≥10 medications (excessive polypharmacy) as chronic or on demand treatments, excluding antiretroviral therapy. Adherence according to the dispensing records.
Enrollment
Prevalence of polypharmacy in the general population in the Basque Country
Časové okno: Enrollment
Proportion of people aged ≥18 years who have ≥5 prescribed medications and ≥10 medications (excessive polypharmacy) as chronic or on demand treatments, excluding antiretroviral therapy. Adherence according to the dispensing records.
Enrollment
Prevalence of potentially inappropriate prescriptions in people with HIV in the Basque Country
Časové okno: Enrollment
Proportion of people with HIV aged ≥18 years who present potentially inappropriate prescriptions according to the STOPP/START criteria: duplications, exceeded maximum doses, contraindicated or severe interactions, anticholinergic burden in people over 70 years of age, and exceeded treatment duration.
Enrollment
Prevalence of potentially inappropriate prescriptions in the general population in the Basque Country
Časové okno: Enrollment
Proportion of people aged ≥18 years who present potentially inappropriate prescriptions according to the STOPP/START criteria: duplications, exceeded maximum doses, contraindicated or severe interactions, anticholinergic burden in people over 70 years of age, and exceeded treatment duration.
Enrollment

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Biogipuzkoa Health Research Institute

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. září 2026

Primární dokončení (Odhadovaný)

1. října 2026

Dokončení studie (Odhadovaný)

1. října 2026

Termíny zápisu do studia

První předloženo

27. května 2026

První předloženo, které splnilo kritéria kontroly kvality

27. května 2026

První zveřejněno (Aktuální)

2. června 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

12. června 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

10. června 2026

Naposledy ověřeno

1. června 2026

Více informací

Termíny související s touto studií

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • 2023111044

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na Žádný zásah

Prohledejte podobné pokusy

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

CROs by country

CROs in Germany

Podmínky

Vzácné nemoci

Drogové intervence

Doplňky stravy

Sponzor / Spolupracovníci

Místa

Předplatit